- Home
- ALLO vs KAZR Comparison
ALLO vs KAZR Comparison
Compare ALLO & KAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.29
HOLD
Current Price
$1.51
Company Overview
Basic Information| Metric | ALLO | KAZR |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 398.1M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ALLO | KAZR |
|---|---|---|
| Price | $1.29 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 143.2K |
| Earning Date | 11-09-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $1.43 |
| 52 Week High | $4.46 | $3.20 |
Technical Indicators
Market Signals| Indicator | ALLO | KAZR |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 31.85 |
| Support Level | $1.22 | N/A |
| Resistance Level | $2.22 | $2.53 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 43.75 | 13.17 |
Price Performance
Historical Comparison ALLO
KAZR
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).